コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 se elimination in health and a developmental brain disorder.
2 pendence has traditionally been considered a brain disorder.
3 wn whether C4 plays a causative role in this brain disorder.
4 p identify the neurobiological principles of brain disorders.
5 hypotheses on disease gene prioritization of brain disorders.
6 ve as a therapeutic target for FXS and other brain disorders.
7 therapeutic targets for the treatment of gut-brain disorders.
8 ntifying biological mechanisms that underlie brain disorders.
9 al drug targets for the treatment of several brain disorders.
10 ctive, mental disorders cannot be reduced to brain disorders.
11 rain aging in healthy individuals and common brain disorders.
12 hrenia, and have potential utility for other brain disorders.
13 iants in the molecular genetic dissection of brain disorders.
14 ns and their genetic architectures in common brain disorders.
15 he pathophysiological role of neuroligins in brain disorders.
16 ltiple neural circuit alterations underlying brain disorders.
17 ay be sites of deregulation in developmental brain disorders.
18 deficient in individuals with SCZ and other brain disorders.
19 n mature neural circuits and are involved in brain disorders.
20 f clinical interventions to treat DA-related brain disorders.
21 munity as a comparative instrument to assess brain disorders.
22 l nervous system and implications in various brain disorders.
23 ic variations observed in complex congenital brain disorders.
24 mental processes and the complex pathways of brain disorders.
25 netics efficiently into new therapeutics for brain disorders.
26 tanding of the role of the receptor in human brain disorders.
27 t can counteract deficits underlying various brain disorders.
28 ge cohorts of individuals with developmental brain disorders.
29 luN2B antagonists with therapeutic value for brain disorders.
30 CKD is linked with various brain disorders.
31 l and genetic heterogeneity of developmental brain disorders.
32 lecularly and used for phenotypic benefit in brain disorders.
33 rable neurons for in vitro investigations of brain disorders.
34 y of this approach for epigenomic studies of brain disorders.
35 hat transcriptionally mimic autism and other brain disorders.
36 on is implicated in the etiology of numerous brain disorders.
37 barrier, could be a precious tool to tackle brain disorders.
38 roRNA profiles have been implicated in human brain disorders.
39 nt novel therapeutic targets in HD and other brain disorders.
40 of candidate genes related to developmental brain disorders.
41 ndividuals with any one of six developmental brain disorders.
42 bition and might contribute to developmental brain disorders.
43 sex-specific susceptibility and severity of brain disorders.
44 y and prevention of delayed complications in brain disorders.
45 n of the resting brain and how it changes in brain disorders.
46 has been increasingly implicated in numerous brain disorders.
47 dysregulation is also implicated in numerous brain disorders.
48 ierarchies in the brain and their defects in brain disorders.
49 h the genesis and/or progression of numerous brain disorders.
50 r challenge to treatment of a broad range of brain disorders.
51 herapeutic implications for neuropsychiatric brain disorders.
52 ognitive processes and their dysfunctions in brain disorders.
53 ion patterns may enable treatment of various brain disorders.
54 applications for amblyopia and other visual brain disorders.
55 ey matter architecture plays in a variety of brain disorders.
56 athophysiological mechanisms in a variety of brain disorders.
57 e, clinical course, and treatment outcome of brain disorders.
58 ssion in the brain has been observed in many brain disorders.
59 potential as therapeutic agents for multiple brain disorders.
60 sy is one of the most common and intractable brain disorders.
61 a common pathologic process in developmental brain disorders.
62 tractive approach for modeling aging-related brain disorders.
63 ially facilitating diagnosis and therapy for brain disorders.
64 rucial to addressing psychiatric symptoms in brain disorders.
65 evelopmental processes common among distinct brain disorders.
66 is known about I/E ratio dynamics in complex brain disorders.
67 provide novel therapeutic targets for adult brain disorders.
68 lopment of precision medicine strategies for brain disorders.
69 their dysfunction is implicated in multiple brain disorders.
70 ove cognitive function and behavior in these brain disorders.
71 o assist in the innovation of treatments for brain disorders.
72 roles in neuronal development, survival, and brain disorders.
73 on is central to the pathogenesis of several brain disorders.
74 ew small-molecule drugs for the treatment of brain disorders.
75 n more than 20 000 subjects and 26 different brain disorders.
76 their dysfunction may contribute to various brain disorders.
77 abnormal than non-hubs in many (if not all) brain disorders.
78 lop cell type-targeted therapeutics to treat brain disorders.
79 ted studies have been performed using PRP in brain disorders.
80 e involved in the pathophysiology of certain brain disorders.
81 lopment, cognition and synaptic pathology of brain disorders.
82 peutic effect of these class of compounds in brain disorders.
83 ble successful genetic analyses of polygenic brain disorders.
84 thophysiology, and treatment of degenerative brain disorders.
85 al processes of multiple sclerosis and other brain disorders.
86 e for a cohort of patients with these common brain disorders.
87 ience and the persistent needs of those with brain disorders.
88 irections and implications for understanding brain disorders.
89 me an essential tool for treating a range of brain disorders.
90 peutics for schizophrenia, and other related brain disorders.
91 g studies in ALS patients and possibly other brain disorders.
92 during resting states that is vulnerable to brain disorders.
93 ance to migraine and other neuroinflammatory brain disorders.
94 s can lead to breakthroughs in treatments of brain disorders.
95 d vessels, and are involved or implicated in brain disorders.
96 resents a significant challenge for treating brain disorders.
97 helpful to understand the pathophysiology of brain disorders.
98 ow Caspr2 dysfunction might lead to specific brain disorders.
99 ed risk of psychosis and other developmental brain disorders.
100 tion transfer, and are disrupted in multiple brain disorders.
101 treatment of various diseases, including the brain disorders.
102 igh GC-content introns and genes involved in brain disorders.
103 outcomes and identifying individual risks of brain disorders.
104 d its impairment has been linked to numerous brain disorders.
105 nd physiological heterogeneity also in other brain disorders.
106 get for the treatment of impulsivity-related brain disorders.
107 thology, contributing to a broad spectrum of brain disorders.
108 disease-modifying strategy for FXS and other brain disorders.
109 r neuronal specialization and is affected by brain disorders.
110 nd challenges of epigenome editing to tackle brain disorders.
111 nt role in many psychiatric and neurological brain disorders.
112 , and can provide therapeutic strategies for brain disorders.
113 ng-state fMRI activity and its disruption in brain disorders.
114 n multiple degenerative and neuropsychiatric brain disorders.
115 a valuable but complex biomarker for several brain disorders.
116 nerable to brain alterations across multiple brain disorders.
117 igue as frequently observed in patients with brain disorders.
118 chanism in other oxidative stress associated brain disorders.
119 ch might underlie vulnerability to cognitive brain disorders.
120 al implications, and possible involvement in brain disorders.
121 increase the risk for numerous developmental brain disorders.
122 rectly associated with Beijing Institute for Brain Disorders, 100069, Beijing, China.This has now bee
123 terations in processes such as aging [4] and brain disorders [5], highlighting the importance of rest
125 or future clinical studies investigating how brain disorders affect brain development or healthy agin
126 ding of how changes in inhibition in complex brain disorders affect I/E dynamics, leading to region-s
129 attern of expression, which occur in several brain disorders, alter synaptic maturation and function
130 d that this mutation underlies the carrier's brain disorder and sought to explore its functional cons
131 nical data from 5062 individuals with common brain disorders and 11,257 healthy controls, we observe
132 to underlie CNS pathophysiology in heritable brain disorders and age-related neurodegenerative and co
133 Neuroinflammation is involved in several brain disorders and can be monitored through expression
134 cal systems, including human diseases (e.g., brain disorders and cancers), plants, and single-cell an
135 Currently, much of the evidence linking brain disorders and circadian dysfunction is correlation
136 iation offer opportunities for understanding brain disorders and developing new technologies for neur
137 understanding the pathological mechanisms of brain disorders and for developing new approaches to eff
138 euromodulation strategy for the treatment of brain disorders and for elucidating the role of neuronal
140 ns in homeostatic mechanisms associated with brain disorders and implications for identifying new tre
142 ongly up-regulated in various forms of acute brain disorders and injuries including epilepsy, stroke
143 MG2G method can be used in studying multiple brain disorders and injuries, e.g., in Parkinson's disea
145 -brain barrier dysfunction is common in most brain disorders and is associated with disease course an
147 nding of how circuit malfunction can lead to brain disorders and outlines the key unmet challenges an
148 brain have a common role in a wide range of brain disorders and point towards potentially shared net
149 patterns of apparent brain aging in several brain disorders and reveal genetic pleiotropy between ap
150 on (DBS) has been used to treat a variety of brain disorders and shows promise in alleviating cogniti
151 g of the neurobiological and mental basis of brain disorders and that such insights will be key to pr
153 brain effects able to reduce future risk of brain disorders and to enhance lifelong brain functions.
154 as its dysregulation could underlie multiple brain disorders and, potentially, other diseases like ca
155 y during adulthood may exacerbate underlying brain disorders and/or worsen recovery from brain stress
156 Cigarette smoking is a chronic relapsing brain disorder, and remains a premier cause of morbidity
158 nitive processes, is compromised in numerous brain disorders, and exhibits a gradual cytoarchitectura
159 ial embryonic lethality, growth retardation, brain disorders, and maternal effect lethality, phenotyp
160 GABAergic synapses have been implied in many brain disorders, and mutations in MET are strong risk fa
161 t to establish that mental disorders are not brain disorders, and that the specific role of networks
162 DRB6, associated with both immunological and brain disorders, and ZFP57, a trans-acting regulator of
166 roteins encoded by genes involved in complex brain disorders are distributed through spatiotemporal p
168 ommon risk factors for psychiatric and other brain disorders are likely to converge on biological pat
170 ging along with an improved understanding of brain disorders are poised to reshape how DBS is viewed
171 leading theory holds that neurodevelopmental brain disorders arise from imbalances in excitatory and
172 l lobe epilepsy (TLE), a common, intractable brain disorder, arises in children with febrile status e
174 linked to the pathogenesis of a spectrum of brain disorders, as well as cancer and several periphera
175 AMPARs are therapeutic targets in a range of brain disorders associated with abnormal glutamate hyper
176 a potential therapeutic target for treating brain disorders associated with dysregulated Dscam expre
178 CC modulators with therapeutic potential for brain disorders associated with impaired ionic homeostas
180 otential of zebrafish tests to model complex brain disorders associated with monoamine dysregulation.
181 elpful in developing the novel therapies for brain disorders associated with the malfunction of Slack
183 psychiatry, a mental disorder can involve no brain disorder at all, even when the former crucially de
184 may provide an entry point for understanding brain disorders at a causal mechanistic level, and that
185 stitutes of Health, McKnight Neuroscience of Brain Disorders award, the Fondo de Investigaciones Sani
186 utes of Health, the McKnight Neuroscience of Brain Disorders award, The Fondo de Investigaciones Sani
187 rapidly becoming a model for human aging and brain disorders but we currently lack any instrument for
188 red hundreds of loci associated with complex brain disorders, but it remains unclear in which cell ty
189 is increasingly applied for the treatment of brain disorders, but its mechanism of action remains unk
190 2 (NPY2) receptors are implicated in diverse brain disorders, but no suitable PET radiotracers are cu
191 ry targeting ciliopathy genes known to cause brain disorders, but whose roles in brain development ar
193 e now being developed for treatment of human brain disorders by direct delivery inside the blood brai
194 reutzfeldt-Jakob disease (CJD), an incurable brain disorder caused by alterations in prion protein st
195 d ataxia constitute a group of heterogeneous brain disorders caused by disruption of several fundamen
198 or the treatment of symptoms associated with brain disorders characterized by cognitive impairment, m
199 functions often impaired in individuals with brain disorders characterized by reduced hippocampal vol
201 SIGNIFICANCE STATEMENT Migraine is a complex brain disorder, characterized by attacks of unilateral h
202 ally treatable neurodevelopmental congenital brain disorder contributing to lifelong neuropsychiatric
203 nce our understanding of the human brain and brain disorders, discuss bioethical considerations, and
204 nriched for genetic variants associated with brain disorders, enabling identification of functional s
208 neuronal excitability, synaptic function and brain disorders has only now begun to be investigated.
214 ld great promise for treating mood and other brain disorders in next-generation therapies that manipu
215 entators agree that mental disorders are not brain disorders in the common interpretation of these te
216 Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact o
217 enes with brain aging and, by extension, for brain disorders in which their expression is decreased.
218 dered a pathophysiological mechanism in many brain disorders including autism spectrum disorder (ASD)
220 ay also contribute to the pathophysiology of brain disorders including schizophrenia and fragile X sy
221 xic stresses involved in the pathogenesis of brain disorders including stroke, and Alzheimer's and Pa
222 in seven other psychiatric and neurological brain disorders (including, among others, major depressi
223 rs (nAChR's) have been implicated in several brain disorders, including addiction, Parkinson's diseas
224 as a novel therapeutic approach to multiple brain disorders, including Alzheimer and Huntington dise
226 potential of zebrafish for modeling complex brain disorders, including attention-deficit/hyperactivi
227 tion, a complication associated with several brain disorders, including autism spectrum disorder (ASD
228 developmental, neurological, and psychiatric brain disorders, including autism spectrum disorders, Pa
230 nd it results in vulnerability to a range of brain disorders, including major depression and cognitiv
231 cations have been documented in a variety of brain disorders, including neurodevelopmental, psychiatr
232 obstacle to the development of therapies for brain disorders, including Parkinson's disease (PD).
233 erogeneity may impede biomarker discovery in brain disorders, including serious mental illnesses.
234 athway are shared characteristics in several brain disorders, including the inherited intellectual di
236 Irritable bowel syndrome (IBS) is a gut-brain disorder involving alterations in intestinal sensi
237 role for DTBM in the investigation of other brain disorders involving white matter hypoplasia or atr
240 of genetic causes among clinically distinct brain disorders is consistent with the concept of develo
241 The potential of exosomes as a therapy for brain disorders is therefore being actively investigated
242 roaches to non-invasively treat a variety of brain disorders is transcranial magnetic stimulation (TM
244 nes implicated in monogenetic forms of other brain disorders or genes encoding excitatory PSD protein
245 L) and PRS(GWAS)), and tested for predicting brain disorders or pathology in independent postmortem e
246 osure to infectious agents to development of brain disorders; others have identified autoantibodies i
247 IK3R2 gene are associated with developmental brain disorders ranging from BPP with a normal head size
255 el the pathogenesis of several developmental brain disorders.SIGNIFICANCE STATEMENT GABA is the major
256 tly identified complement gene mutations and brain disorders.SIGNIFICANCE STATEMENT The complement sy
258 CYP46A1 activity as a therapeutic target of brain disorders such as Alzheimer's disease, for which c
261 (Dscam) is implicated in the pathogenesis of brain disorders such as Down syndrome (DS) and fragile X
262 ance in synaptic transmission underlies many brain disorders such as epilepsy, schizophrenia, and aut
267 AP1/Syngap1 commonly occurs in developmental brain disorders, such as intellectual disability, epilep
268 of these oscillations has been implicated in brain disorders, such as schizophrenia and Alzheimer's d
269 hibitory synapses is associated with complex brain disorders, such as schizophrenia and epilepsy.
271 ed genes, suggesting that the differences in brain disorder susceptibility between males and females
274 common, disabling, and undertreated episodic brain disorder that is more common in women than in men.
276 e brain's memory management system and human brain disorders that alter active forgetting mechanisms.
277 d as anesthetic agents and as drugs to treat brain disorders that are ameliorated by positive alloste
278 F14 gene in humans have been associated with brain disorders that are partially recapitulated in Fgf1
280 old promise for defining the pathogenesis of brain disorders that have resisted simple molecular desc
281 hyperactivity disorder (ADHD) are widespread brain disorders that involve disturbances of dopaminergi
282 e (PD) and schizophrenia (SCZ) are heritable brain disorders that involve dysregulation of the dopami
283 gation of important underlying mechanisms of brain disorders that is not possible through neural reco
284 l application of B. caapi alkaloids to other brain disorders that may benefit from stimulation of end
286 channelopathies represent a growing class of brain disorders that usually result in paroxysmal disord
289 utes of Health, the McKnight Neuroscience of Brain Disorders, the Fondo de Investigaciones Sanitarias
290 nvestigations of neurobiological markers for brain disorders, the number of multi-site studies involv
291 ave been reported in the vascular-associated brain disorders, the roles of TLJN in AD brains are stil
292 be circadian disruptions observed in various brain disorders throughout the human lifespan and highli
295 zebrafish in modeling a wide range of human brain disorders, we also summarize recent applications a
296 imaging lesions that were common across all brain disorders were more likely to be located in hubs o
299 data should inform treatment strategies for brain disorders with impaired motivation such as schizop
300 rk of many neurodegenerative and psychiatric brain disorders, yet we know little about the mechanisms